Moderator
Doug Foster, MBA, Advanced Data Sciences LLC, San Francisco, CA, United States
Speakers
Ryan Ahern, Truveta, Bellevue, WA, United States; Pamela Tenaerts, MBA, MD, Medable, Palo Alto, CA, United States; Reza Yaesoubi, PhD, University of California, San Francisco, San Francisco, CA, United States; Claudia Grossmann, PhD, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, United States
Evidence generation sits at the heart of healthcare investment decisions, yet its cost remains one of the most significant barriers to bringing innovations to market.
This panel brings together experts to explore the core drivers of these costs and how emerging tools are changing the equation. Technologies like decentralized designs, AI-powered patient matching, remote patient monitoring and synthetic control arms will be a primary focus. Combining RCTs with real-world data bring additional potential savings with RWD-constructed external comparator arms, improving data interoperability, and improving RWD accessibility.
The panel discusses a direct message to investors: companies that embed evidence generation efficiency into their development strategy from the outset can compress timelines, reduce capital requirements, and de-risk the path to approval and reimbursement.
Topic
Methodological & Statistical Research